These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23490268)

  • 1. The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer.
    Everitt S; Plumridge N; Herschtal A; Bressel M; Ball D; Callahan J; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; Mac Manus M
    Radiother Oncol; 2013 Mar; 106(3):288-91. PubMed ID: 23490268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.
    Mac Manus MP; Everitt S; Bayne M; Ball D; Plumridge N; Binns D; Herschtal A; Cruickshank D; Bressel M; Hicks RJ
    Radiother Oncol; 2013 Mar; 106(3):292-8. PubMed ID: 23541364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
    Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
    Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-based
    Chen HHW; Su WC; Guo HR; Lee BF; Chiu NT
    Kaohsiung J Med Sci; 2019 Mar; 35(3):151-159. PubMed ID: 30887722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.
    Mac Manus MP; Hicks RJ
    Semin Nucl Med; 2012 Sep; 42(5):308-19. PubMed ID: 22840596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
    AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer.
    Lin P; Koh ES; Lin M; Vinod SK; Ho-Shon I; Yap J; Som S
    Radiother Oncol; 2011 Nov; 101(2):284-90. PubMed ID: 21777988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
    Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cone-beam computed tomography for lung cancer - validation with CT and monitoring tumour response during chemo-radiation therapy.
    Michienzi A; Kron T; Callahan J; Plumridge N; Ball D; Everitt S
    J Med Imaging Radiat Oncol; 2017 Apr; 61(2):263-270. PubMed ID: 27804280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of third treatment week as temporal window for assessing responsiveness on repeated FDG-PET-CT scans in Non-Small Cell Lung Cancer patients.
    Lazzeroni M; Uhrdin J; Carvalho S; van Elmpt W; Lambin P; Dasu A; Wersäll P; Toma-Dasu I
    Phys Med; 2018 Feb; 46():45-51. PubMed ID: 29519408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.